Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PK Study of Clofazimine Combination Therapy in Japanese Pulmonary MABC Disease (MYCAT)
jRCT2031220211Phase 1Completed
- Start
- Aug 2022
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of clofazimine in Mycobacterium abscessus lung disease. Primary endpoint: PK/PD of clofazimine and combination antibiotics. Started Aug 2022; status: completed.
02
Drugs
clofazimine
03
Conditions
Mycobacterium abscessus lung disease
Beyond the preview
Go deeper on jRCT2031220211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220211.